Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chi-Med Signs Collaboration With Lilly For Oncology, Inflammation Candidates

This article was originally published in PharmAsia News

Executive Summary

Chi-Med's wholly owned research and development subsidiary Hutchison MediPharma will collaborate with Eli Lilly on the discovery and development of pharmaceutical targets in oncology and inflammation, Chi-Med announced Aug. 20
Advertisement

Related Content

Hutchison MediPharma's Solid Tumor Drug First Oncology Project To Enter SFDA Fast-track Approval
Hutchison MediPharma's Solid Tumor Drug First Oncology Project To Enter SFDA Fast-track Approval
Eli Lilly In Asia Expansion Overdrive
Eli Lilly In Asia Expansion Overdrive
A Sign of the Times: Chi-Med’s MediPharma Steps Toward Independence
A Sign of the Times: Chi-Med’s MediPharma Steps Toward Independence
Asian CROs On The March, But Tie-Ups Carry Risk: Analyst
Asian CROs On The March, But Tie-Ups Carry Risk: Analyst
China IND Requirements Overly Burdensome To Industry – Shanghai R&D Summit
Merck KGaA Looks To Chinese Medicine For Oncology Candidates
Advertisement
UsernamePublicRestriction

Register

SC066455

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel